Navigation Links
FDA Approves New Treatment Option for Late-Stage Breast Cancer
Date:11/15/2010

SILVER SPRING, Md., Nov. 15, 2010 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Breast cancer is the second leading cause of cancer related death among women, according to the National Cancer Institute.  This year, an estimated 207,090 women will be diagnosed with breast cancer, while 39,840 women will die from the disease.

Halaven is a synthetic form of a chemotherapeutically active compound derived from the sea sponge Halichondria okadai. This injectable therapy is a microtubule inhibitor, believed to work by inhibiting cancer cell growth. Before receiving Halaven, patients should have received prior anthracycline- and taxane-based chemotherapy for early or late-stage breast cancer.

Halaven's safety and effectiveness were established in a single study in 762 women with metastatic breast cancer who had received at least two prior chemotherapy regimens for late-stage disease. Patients were randomly assigned to receive treatment with either Halaven or a different single agent therapy chosen by their oncologist.

The study was designed to measure the length of time from when this treatment started until a patient's death (overall survival). The median overall survival for patients receiving Halaven was 13.1 months compared with 10.6 months for those who received a single agent therapy.

"There are limited treatment options for women with aggressive forms of late-stage breast cancer who have already received other therapies," said Richard Pazdur, M.D., direct
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHAPEL HILL, N.C. , Jan. 23, 2015 For ... organizations are in dealing with payers. Likewise, the importance of ... payers - will only continue to grow as payer formularies ... patients access therapies. At the same time, managed ...
(Date:1/23/2015)... LOS ANGELES , Jan. 23, 2015 A lot ... the best methods for treating  certain illnesses, injuries, or conditions. ... to replace previous treatment methods with ones that they consider ... treating hernias, there is not one textbook method of treatment ...
(Date:1/23/2015)... 23, 2015  A new analysis of Centers for Medicare ... data shows that 81 percent of seniors chose lower-cost ... discounts at certain pharmacies. The findings were released by ... are now the foundation of Medicare Part D," said ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2No One-Size-Fits-All Remedy for Hernia Correction 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2
... A milestone in lupus research was met this weekend!  On ... held its 8th annual New York City Walk with Us ... matched by the enthusiasm of the nearly 3000 walkers in attendance ... master of ceremonies, My9 news anchor Brenda Blackmon, ALR Chairman Robert ...
... LOUIS, Oct. 27, 2011 Express Scripts, Inc. (Nasdaq: ... following investor conferences in November: Credit Suisse 2011 ... mountain (9:30 a.m. eastern). Lazard Capital Markets, 8th ... a.m. eastern. These presentations will also be ...
Cached Medicine Technology:Alliance for Lupus NYC Walk With Us to Cure Lupus First Lupus Walk In History To Raise $1-Million 2
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... macular degeneration (AMD)including an intravitreous (into the eye) injection ... compound approved for use against the eye diseasedo not ... cardiovascular complications or death when compared with existing therapies, ... Archives of Ophthalmology , one of the JAMA/Archives ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... your dog home alone without having to worry about chewed ... how to look at the sunny side of life. ... more likely to become distressed and anxious when left alone ...
... , SUNDAY, Oct. 10 (HealthDay News) -- Scientists have found ... for obesity. The findings are reported in two new ... Nature Genetics . , In one report, researchers say they ... the involvement of 14 others. In a second report, the ...
... 2010 A clinical trial at UT Southwestern Medical ... to standard insulin therapy might help rein in the ... diabetes. This is the first type 1 diabetes ... fat cells and involved in body-weight regulation. For this ...
... and structured weight loss programs, can result in significant weight ... two reports that were posted online today by JAMA ... early online to coincide with the presentation of these papers ... The articles will appear in the October 27 print ...
... at UT Southwestern Medical Center have created an experimental ... in the brain and is believed to contribute to ... similar so-called DNA vaccines that the UT Southwestern researchers ... stimulated more than 10 times as many antibodies that ...
Cached Medicine News:Health News:Certain new therapies for age-related eye disease do not appear to increase heart risks 2Health News:Pessimistic Pooches May Be Prone to Separation Anxiety 2Health News:Pessimistic Pooches May Be Prone to Separation Anxiety 3Health News:Researchers Pinpoint Array of Obesity Genes 2Health News:Researchers Pinpoint Array of Obesity Genes 3Health News:UT Southwestern study to determine whether leptin helps type 1 diabetes patients 2Health News:UT Southwestern study to determine whether leptin helps type 1 diabetes patients 3Health News:Clinical trials demonstrate effective weight loss strategies for obese and overweight adults 2Health News:Clinical trials demonstrate effective weight loss strategies for obese and overweight adults 3Health News:UT Southwestern researchers create experimental vaccine against Alzheimer's 2
The Thrombex PMT system is a self-contained, disposable clot-removal device that uses a motor-driven catheter and vacuum source to break up and remove thrombi from a hemodialysis graft....
... AngioJet Xpeedior+120 Rheolytic Thrombectomy catheter is designed ... Powerful saline jets create a low pressure ... vacuum effect. Thrombus is drawn into the ... jets, and removed from the body.,AngioJet thrombectomy ...
... pulse generators are meeting the clinical ... electrophysiologists and anesthesiologists. And, they are ... expect from Medtronic.,Effective pacing with the ... polarity for quick battery changes. ...
... St. Jude Medical offers the world's ... Pacel bipolar pacing catheters are available in ... a broad range of curve choices and ... Pacing Catheter is indicated for use in ...
Medicine Products: